The scientific minds informing our innovative approach
Our Scientific Advisory Board combines years of medical and discovery experience, clinical research activity, and regulatory expertise.
Scientific Advisory Board
William Sandborn, M.D.
Chairman of Scientific Advisory Board
Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda, California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota, in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011, he joined the University of California San Diego (UCSD) as a Professor of Medicine, and from 2011-2021, he was Director of the IBD Center and Chief of the Division of Gastroenterology at UCSD. Since 2021, he has continued as a Distinguished Professor of Medicine at UCSD. He was previously a co-founder of Santarus, working directly with Scott Glenn, Stephan Targan, and Gerry Proehl. Dr. Sandborn is also a co-founder and the Chief Medical Officer of Shoreline Biosciences. He has published over 752 peer-reviewed articles and is a member of the editorial board for the New England Journal of Medicine.
Donna Griebel, M.D.
Dr. Donna Griebel is former Director of the Division of Gastroenterology and Inborn Errors Products (DGIEP) with the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). As acting Director, she regulated Investigational New Drug Applications (NDAs) and Biologics Licensing Applications (BLAs) for drugs and therapeutic biologics intended for the treatment and prevention of gastrointestinal, hepatic, and nutritional disorders and inborn errors of metabolism. In her prior position, Dr. Griebel was Deputy Director of the Division of Reproductive and Urologic Products, where she oversaw the safety and efficacy of drugs and therapeutic biologics aimed to improving reproductive and urologic health. She has extensive regulatory experience in drug development and served on CDER’s Medical Policy Council (MPC) and MPC’s Subcommittee on Safety Outcome Trials.
Dermot McGovern, M.D., Ph.D.
Dr. Dermot McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a Ph.D. in complex disease genetics at the University of Oxford, England, before moving to Cedars-Sinai. Dr. McGovern is Director of Translational Medicine at Cedars-Sinai, Co-Director of the Cedars-Sinai IBD Repository (MIRIAD) and IBD Database, and was recently appointed the Director of Precision Health at Cedars-Sinai. Dr. McGovern serves on both the Steering Committee of the NIDDK IBD Genetics Consortium and on the Management Committee of the International IBD Genetics Consortium. Dr. McGovern is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences, and serves as the consulting geneticist and provides input on the patient selection criteria.
Luisa Salter-Cid, Ph.D.
Dr. Luisa Salter-Cid is the Chief Scientific Officer of Pioneering Medicines, the new R&D division of Flagship Pioneering. Previously, she served as the Chief Scientific Officer of Gossamer Bio, where she oversaw a research team focused on bringing immunology-based innovative medicines up to IND filing. Prior to joining Gossamer, Dr. Salter-Cid spent 13 years at Bristol Myers Squibb, where she held several positions, including Vice President and Head of Immunology, Small Molecule Immuno-Oncology and Genomics Discovery. In this position, she oversaw several biology groups that focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at Bristol Myers Squibb, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development. She was also Chair of the Immunoscience Target Science Team (TST) and a core member of several executive committees focused on strategy, development, and external collaborations. Prior to joining Bristol Myers Squibb, she was a Senior Project Leader at La Jolla Pharmaceuticals, where she led discovery projects. She also held positions at Genset Corp and Johnson & Johnson.
Bruce E. Sands, M.D.
Dr. Bruce E. Sands is the head of the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York, NY. He also serves as the Dr. Burrill B. Crohn’s Professor and Chief of Gastroenterology at Mount Sinai. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn’s & Colitis Center at Massachusetts General Hospital in Boston, Massachusetts, where he also served as the hospital’s Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. He is a fellow of the American College of Gastroenterology and the American Gastroenterological Association and is reviewer for the New England Journal of Medicine. Dr. Sands received his medical degree at Boston University School of Medicine and completed a residency in internal medicine at the Hospital of the University of Pennsylvania. He then completed clinical and research fellowships at Massachusetts General Hospital. In 2001, Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Stephan Targan, M.D.
Dr. Stephan Targan is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences, and is currently the Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center. Dr. Targan began his career at UCLA School of Medicine in 1978 and then moved his laboratories and practice in 1992 to establish the IBD Center at Cedars-Sinai. Dr. Targan has focused on identifying drivers of IBD pathogenesis which, in the context of such a genetically heterogenous disease, involves numerous biological and molecular pathways and compromises complex relationships between the intestinal microenvironment and the immune response. With over 4 decades of experience in treating IBD patients and over 300 peer-reviewed articles, Dr. Targan is a recognized leader in inflammatory bowel diseases. He was previously a co-founder of Santarus and Prometheus Laboratories.
Brian G. Feagan, M.D.
Dr. Brian G. Feagan is a gastroenterologist, epidemiologist, and Senior Scientific Director at Alimentiv. He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 400 articles.